Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | AGER | Q15109 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20746511 | 1.00 | CYP2C19 (0.53) | CYP2C19CYP1A2KMT2AATMMAPT | |
| SCHEMBL22655999 | 1.00 | CYP2C19 (0.53) | CYP2C19CYP1A2KMT2AATMMAPT | |
| Glycerin SCHEMBL3630101 | 0.87 | ALDH1A1 (0.46) | CYP2C19CYP1A2KMT2AMAPTLMNA | |
| Glycerin SCHEMBL2058190 | 0.87 | ALDH1A1 (0.46) | CYP2C19CYP1A2KMT2AMAPTLMNA | |
| Glycerin SCHEMBL28301031 | 0.87 | ALDH1A1 (0.46) | CYP2C19CYP1A2KMT2AMAPTLMNA | |
| Glycerin SCHEMBL11517976 | 0.82 | ALDH1A1 (0.43) | CYP2C19CYP1A2KMT2AMAPTLMNA | |
| SCHEMBL6309824 | 0.81 | CYP1A2 (0.52) | CYP2C19CYP1A2KMT2AATMMAPT | |
| SCHEMBL2057584 | 0.81 | THRB (0.43) | CYP2C19CYP1A2KMT2AMAPTLMNA | |
| SCHEMBL6317104 | 0.81 | CYP1A2 (0.52) | CYP2C19CYP1A2KMT2AATMMAPT | |
| SCHEMBL6361661 | 0.81 | CYP1A2 (0.52) | CYP2C19CYP1A2KMT2AATMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364248-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20200360399-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2020-11-19 | — | — | US | disclosed |
| EP-3668878-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | Amgen Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019036575-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360399-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | CYP2C19 4127/4885CYP1A2 3986/4885KMT2A 1644/4885 |
| US-11364248-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | CYP2C19 4127/4885CYP1A2 3986/4885KMT2A 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.